Clinical studies of bay o 9867 (ciprofloxacin)in skin infections

Masutaka Furue, Sook Hyang Yoon, Hong Il Yoon, Naoshige Horie, Yasuo Kubota, Kimiko Ogawa, Shotaro Harada

Research output: Contribution to journalArticlepeer-review


The clinical efficacy of BAY o 9867, a new quinoline carboxylic acid derivative, was studied in dermatological infectious diseases. BAY o 9867 was administered to 33 patients with various skin infectious diseases. The dose was 300~600mg and the duration of administration was 3 to 17 days. The isolated organisms from affected sites were S. aureus, S. epidermidis, P. acnes, S. capitis, Peptostreptococcus, P. avidum, S. pyogenes, S. xylosus. S. aureus and S. epidermidis were all eliminated. Clinical results were excellent in 8 cases, good in 21cases, fair in 2 cases and poor in 2 cases. The overall efficacy rate was 87.9%. As the side effect of BAY o 9867, mild heartburn was noted in 1 case. As the abnormal changes in laboratory data, slight increase of BUN was found in only 1 case.

Original languageEnglish
Pages (from-to)946-950
Number of pages5
Publication statusPublished - Jan 1 1985
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Clinical studies of bay o 9867 (ciprofloxacin)in skin infections'. Together they form a unique fingerprint.

Cite this